Clinical Trials · NCT05869903
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 3,127
- Start date
- Jun 2023
- Locations
- 138 sites, 10 countries
- Primary endpoint
- Mean Percent Change from Baseline in Body Weight